BiomX (PHGE) Cash from Financing Activities (2018 - 2026)
BiomX (PHGE) posted Cash from Financing Activities of $2.6 million for Q1 2026, up 109.67% sequentially from $1.3 million in Q4 2025, and down 77.98% YoY from $11.9 million in Q1 2025.
BiomX (PHGE) Cash from Financing Activities (2018 - 2026) Analysis & Trends
BiomX has reported Cash from Financing Activities for 9 years, with the latest figure at $2.6 million in Q1 2026.
- Quarterly Cash from Financing Activities fell 77.98% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (down 65.53% YoY) and the FY2025 annual result came in at $13.2 million, down 65.63% from the prior year.
- Cash from Financing Activities climbed to $2.6 million in Q1 2026 per PHGE's latest filing, from $1.3 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $11.9 million in Q1 2025 and troughed at -$1.3 million in Q4 2023.
- A 5-year average of $1.3 million and a median of $45500.0 in 2022 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 23478.95% in 2023, down 653.81% in 2023.
- Over 5 years, Cash from Financing Activities stood at $236000.0 in 2022, then slumped by 661.02% to -$1.3 million in 2023, then surged by 69.94% to -$398000.0 in 2024, then soared by 414.32% to $1.3 million in 2025, then jumped by 109.67% to $2.6 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $2.6 million, $1.3 million, and $54000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | BiomX | 351,774.34 | -816,225.66 | - | 2.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.62 Mn |
| Mar 31, 2026 | 2.62 Mn |
| Dec 31, 2025 | 1.25 Mn |
| Dec 31, 2025 | 1.25 Mn |
| Sep 30, 2025 | 54,000.00 |
| Sep 30, 2025 | 54,000.00 |
| Jun 30, 2025 | -29,000.00 |
| Jun 30, 2025 | -29,000.00 |
| Mar 31, 2025 | 11.91 Mn |
| Mar 31, 2025 | 11.91 Mn |
| Dec 31, 2024 | -398,000.00 |
| Dec 31, 2024 | -398,000.00 |
| Jun 30, 2024 | -203,000.00 |
| Jun 30, 2024 | -203,000.00 |
| Dec 31, 2023 | -1.32 Mn |
| Dec 31, 2023 | -1.32 Mn |
| Sep 30, 2023 | -1.31 Mn |
| Sep 30, 2023 | -1.31 Mn |
| Jun 30, 2023 | 4.48 Mn |
| Jun 30, 2023 | 4.48 Mn |